ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Immunology
インパクトファクター: 1.352 5年インパクトファクター: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN 印刷: 1040-8401
ISSN オンライン: 2162-6472

巻:
巻 39, 2019 巻 38, 2018 巻 37, 2017 巻 36, 2016 巻 35, 2015 巻 34, 2014 巻 33, 2013 巻 32, 2012 巻 31, 2011 巻 30, 2010 巻 29, 2009 巻 28, 2008 巻 27, 2007 巻 26, 2006 巻 25, 2005 巻 24, 2004 巻 23, 2003 巻 22, 2002 巻 21, 2001 巻 20, 2000 巻 19, 1999 巻 18, 1998 巻 17, 1997 巻 16, 1996 巻 15, 1995 巻 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v27.i6.20
pages 511-525

Application of Natural Killer T Cells in Antitumor Immunotherapy

Changwan Hong
School of Life Sciences and Biotechnology, Korea University, Seoul 136-701, Republic of Korea
Se-Ho Park
School of Life Sciences and Biotechnology, Korea University, Seoul 136-701, Republic of Korea

要約

NKT cells are a unique subset of T cells that recognize glycolipid antigens presented by CD1d molecules. NKT cells have the potential to produce key cytokines of both Th1 and Th2 T cells and are involved in the control of several types of immune response. Furthermore, NKT cells perform spontaneous tumor immunosurveillance. Upon specific activation with α-GalCer, NKT cells show strong antitumor immune responses through direct cytotoxicity and indirect activation of a cascade of antitumor effector cells such as natural killer (NK) cells and CD8+ cytotoxic T cells. In addition to α-GalCer, many other CD1d ligands, including self and bacterial glycolipids and modified synthetic glycolipid antigens, have also been discovered. Structurally different glycolipid antigens have the distinct ability to activate NKT cells. Thus, it seems that we are now close to a position in which we can control the activation status of NKT cells; this makes NKT cells an ideal target of anticancer immunotherapies. Clinical trials with soluble α-GalCer or α-GalCer-pulsed dendritic cells aimed at in vivo reconstitution and activation of human NKT cells have provided both promising and challenging results. In this review, we discuss NKT-cell-mediated antitumor immune responses, as well as the early outcomes and implications of recent clinical studies.


Articles with similar content:

Orchestration of Invariant Natural Killer T Cell Development by E and Id Proteins
Critical Reviews™ in Immunology, Vol.35, 2015, issue 1
Yuan Zhuang, Sumedha Roy
iNKT-Cell Responses to Glycolipids
Critical Reviews™ in Immunology, Vol.25, 2005, issue 3
Luc Van Kaer, Vrajesh V. Parekh, Michael T. Wilson
IL-21 Is an Immune Activator That also Mediates Suppression via IL-10
Critical Reviews™ in Immunology, Vol.30, 2010, issue 6
Warren J. Leonard, Rosanne Spolski
CD1d-Mediated Antigen Presentation to Natural Killer T (NKT) Cells
Critical Reviews™ in Immunology, Vol.23, 2003, issue 5-6
Tonya J. Roberts, Venkataraman Sriram, Yinling Lin, Sungyoo Cho, Randy R. Brutkiewicz, Yu Kyeong Hwang
Dendritic Cell Cross Talk with Innate and Innate-like Effector Cells in Antitumor Immunity: Implications for DC Vaccination
Critical Reviews™ in Immunology, Vol.34, 2014, issue 6
I. Jolanda M. de Vries, Jasper J. P. van Beek, Annette E. Skold, Stanleyson V. Hato, Florian Wimmers